Glucocorticoid corticosteroids for Duchenne muscular dystrophy

医学 德菲扎科特 杜氏肌营养不良 物理疗法 神经肌肉疾病 肌营养不良 浪费的 不利影响 强的松 临床试验 儿科 内科学 疾病
作者
Adnan Y. Manzur,Thierry Küntzer,Mike Pike,A V Swan
出处
期刊:Cochrane Database of Systematic Reviews 被引量:516
标识
DOI:10.1002/14651858.cd003725.pub2
摘要

Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood. This incurable disease is characterised by muscle wasting and loss of walking ability leading to complete wheelchair dependence by 13 years of age. Prolongation of walking is one of the major aims of treatment.The aim of this review was to assess whether glucocorticoid corticosteroids stabilize or improve muscle strength and walking in boys with DMD.This is an update of the Cochrane systematic review first published in 2004 (Manzur 2004). We searched the Cochrane Neuromuscular Disease Group Trials Register (August 2006) using the term 'Duchenne muscular dystrophy'. We also searched MEDLINE (January 1966 to July 2007), EMBASE (January 1980 to August 2006), CINAHL and LILACS (January 1982 to August 2006). We wrote to authors of published studies and other experts in this disease to help identify other trials, checked the references in the identified trials and hand searched the abstracts of relevant journals.Types of studies: randomised or quasi-randomised trials.all patients with a definite diagnosis of Duchenne muscular dystrophy. Types of interventions: glucocorticoids such as prednisone, prednisolone, deflazacort or others, with a minimum treatment period of three months.prolongation of walking (independent walking without long leg calipers).strength outcome measures, manual muscle strength testing using Medical Research Council strength scores, functional outcome measures and adverse events.We identified six randomised controlled trials that met the inclusion criteria for our review, and one of these (Beenakker 2005) is a new addition to this update, as it was published subsequent to our first review (Manzur 2004). Two review authors independently selected the trials for the review and assessed methodological quality. Data extraction and inputting were double-checked.data from one small study used prolongation of walking as an outcome measure and did not show significant benefit.The meta-analysis of the results from four randomised controlled trials with altogether 249 participants showed that glucocorticoid corticosteroids improved muscle strength and function over six months. Improvements were seen in time taken to rise from the floor (Gowers' time), nine metres walking time, four-stair climbing time, ability to lift weights, leg function grade and forced vital capacity. One randomised controlled trial with altogether 28 participants showed that glucocorticoid corticosteroids stabilize muscle strength and function for up to two years. The most effective prednisolone regime appears to be 0.75 mg/kg/day, given in a daily dose regime. Not enough data were available to compare efficacy of prednisone with deflazacort. Adverse effects: Excessive weight gain, behavioural abnormalities, cushingoid appearance and excessive hair growth were all more common with glucocorticoid corticosteroids than placebo. Long-term adverse effects of glucocorticoid therapy could not be evaluated because of the short-term duration of the randomised studies.Non-randomised studies: A number of non-randomised studies with important efficacy and adverse effects data are tabulated and discussed.There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years). The most effective prednisolone regime appears to be 0.75 mg/kg/day, given daily. In the short term, adverse effects were significantly more common but not clinically severe. Long-term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomised studies. Non-randomised studies support the conclusions of functional benefits but also identify clinically significant adverse effects of long-term treatment. These benefits and adverse effects have implications for future research studies and clinical practice.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
烟花应助UP采纳,获得10
刚刚
刚刚
科研牛马完成签到,获得积分10
1秒前
1秒前
1秒前
1秒前
巧克力豆发布了新的文献求助10
2秒前
2秒前
3秒前
cocolu应助coolkid采纳,获得10
3秒前
CG2021发布了新的文献求助10
4秒前
4秒前
爱笑发布了新的文献求助10
5秒前
Ganlou应助xiaolu采纳,获得10
5秒前
5秒前
5秒前
高大的易蓉完成签到,获得积分10
5秒前
6秒前
aldehyde完成签到,获得积分0
6秒前
欣喜沛柔完成签到,获得积分20
6秒前
7秒前
星辰大海应助眉间一把刀采纳,获得10
7秒前
月颜发布了新的文献求助10
7秒前
7秒前
8秒前
纳若w完成签到,获得积分10
8秒前
9秒前
9秒前
9秒前
彭珊发布了新的文献求助10
9秒前
科研通AI2S应助巧克力豆采纳,获得10
9秒前
10秒前
热心初阳发布了新的文献求助10
10秒前
10秒前
leihai发布了新的文献求助10
10秒前
10秒前
故笺发布了新的文献求助10
10秒前
楠楠发布了新的文献求助30
10秒前
10秒前
李爱国应助小李要努力Oo采纳,获得10
11秒前
高分求助中
Licensing Deals in Pharmaceuticals 2019-2024 3000
Cognitive Paradigms in Knowledge Organisation 2000
Effect of reactor temperature on FCC yield 2000
Introduction to Spectroscopic Ellipsometry of Thin Film Materials Instrumentation, Data Analysis, and Applications 600
Promoting women's entrepreneurship in developing countries: the case of the world's largest women-owned community-based enterprise 500
Shining Light on the Dark Side of Personality 400
Analytical Model of Threshold Voltage for Narrow Width Metal Oxide Semiconductor Field Effect Transistors 350
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3309200
求助须知:如何正确求助?哪些是违规求助? 2942533
关于积分的说明 8509490
捐赠科研通 2617712
什么是DOI,文献DOI怎么找? 1430268
科研通“疑难数据库(出版商)”最低求助积分说明 664108
邀请新用户注册赠送积分活动 649272